EBS
Emergent BioSolutions Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$472M
5Y Perf.-89.8%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
EBS vs SIGA vs PRGO vs BRKR vs ABCL
Revenue, margins, valuation, and 5-year total return — side by side.
SIGA
SIGA Technologies, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$339M
5Y Perf.-34.9%
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.61B
5Y Perf.-73.8%
BRKR
Bruker Corporation
Medical - Devices
Market Cap$6.66B
5Y Perf.-19.2%
ABCL
AbCellera Biologics Inc.
Biotechnology
Market Cap$1.45B
5Y Perf.-88.0%
EBS vs SIGA vs PRGO vs BRKR vs ABCL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | EBS | SIGA | PRGO | BRKR | ABCL |
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Medical - Devices | Biotechnology |
| Market Cap | $472M | $339M | $1.61B | $6.66B | $1.45B |
| Revenue (TTM) | $743M | $94M | $4.18B | $3.46B | $75M |
| Net Income (TTM) | $53M | $-4.04T | $-1.82B | $-12M | $-146M |
| Gross Margin | 47.1% | 61.8% | 34.2% | 45.3% | -48.2% |
| Operating Margin | 14.7% | 27.7% | -4.1% | 4.9% | -402.1% |
| Forward P/E | 17.6x | 2.8x | 5.6x | 20.7x | — |
| Total Debt | $572M | $595K | $3.97B | $2.04B | $137M |
| Cash & Equiv. | $205M | $155M | $532M | $299M | $129M |
EBS vs SIGA vs PRGO vs BRKR vs ABCL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EBS
SIGA
PRGO
BRKR
ABCL
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Emergent BioSolutio… (EBS) | 100 | 10.2 | -89.8% |
| SIGA Technologies, … (SIGA) | 100 | 65.1 | -34.9% |
| Perrigo Company plc (PRGO) | 100 | 26.2 | -73.8% |
| Bruker Corporation (BRKR) | 100 | 80.8 | -19.2% |
| AbCellera Biologics… (ABCL) | 100 | 12.0 | -88.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EBS vs SIGA vs PRGO vs BRKR vs ABCL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SIGA leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Emergent BioSolutions Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. ABCL also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
EBS
Emergent BioSolutions Inc.
The Quality Compounder
EBS is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 7.1% margin vs SIGA's -43K%
- 3.7% ROA vs ABCL's -23.3%, ROIC 8.5% vs -16.8%
Best for: quality and efficiency
SIGA
SIGA Technologies, Inc.
The Income Pick
SIGA carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 4 yrs, beta 1.15, yield 12.7%
- 7.6% 10Y total return vs BRKR's 67.1%
- Lower volatility, beta 1.15, Low D/E 0.3%, current ratio 11.83x
- Beta 1.15, yield 12.7%, current ratio 11.83x
Best for: income & stability and long-term compounding
PRGO
Perrigo Company plc
The Income Angle
PRGO lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
BRKR
Bruker Corporation
The Healthcare Pick
Among these 5 stocks, BRKR doesn't own a clear edge in any measured category.
Best for: healthcare exposure
ABCL
AbCellera Biologics Inc.
The Growth Play
ABCL ranks third and is worth considering specifically for growth exposure.
- Rev growth 160.6%, EPS growth 10.9%, 3Y rev CAGR -46.3%
- 160.6% revenue growth vs SIGA's -31.8%
- +139.8% vs PRGO's -51.2%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ABCL | 160.6% revenue growth vs SIGA's -31.8% |
| Value | SIGA | Better valuation composite |
| Quality / Margins | EBS | 7.1% margin vs SIGA's -43K% |
| Stability / Safety | SIGA | Beta 1.15 vs ABCL's 2.31, lower leverage |
| Dividends | SIGA | 12.7% yield, 4-year raise streak, vs PRGO's 9.8%, (2 stocks pay no dividend) |
| Momentum (1Y) | ABCL | +139.8% vs PRGO's -51.2% |
| Efficiency (ROA) | EBS | 3.7% ROA vs ABCL's -23.3%, ROIC 8.5% vs -16.8% |
EBS vs SIGA vs PRGO vs BRKR vs ABCL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
EBS vs SIGA vs PRGO vs BRKR vs ABCL — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSIGALAGGINGABCL
Who Leads Where
SIGA leads in 3 of 6 categories
EBS leads 0 • PRGO leads 0 • BRKR leads 0 • ABCL leads 0 • 3 tied
Explore the data ↓ABCLAbCellera Biologics I…
0leads
BRKRBruker Corporation
0leads
PRGOPerrigo Company plc
0leads
EBSEmergent BioSolutions…
0leads
SIGASIGA Technologies, In…
3leads
6 Total Categories
CATEGORYLEADERvs EBSvs PRGOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SIGA3/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SIGA5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
SIGA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
SIGA leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 55.6x ABCL's $75M. EBS is the more profitable business, keeping 7.1% of every revenue dollar as net income compared to SIGA's -43117.4%. On growth, ABCL holds the edge at +7.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | EBSEmergent BioSolut… | SIGASIGA Technologies… | PRGOPerrigo Company p… | BRKRBruker Corporation | ABCLAbCellera Biologi… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $743M | $94M | $4.2B | $3.5B | $75M |
| EBITDAEarnings before interest/tax | $207M | $26M | $58M | $397M | -$280M |
| Net IncomeAfter-tax profit | $53M | -$4.04T | -$1.8B | -$12M | -$146M |
| Free Cash FlowCash after capex | $157M | $33M | $108M | $51M | -$174M |
| Gross MarginGross profit ÷ Revenue | +47.1% | +61.8% | +34.2% | +45.3% | -48.2% |
| Operating MarginEBIT ÷ Revenue | +14.7% | +27.7% | -4.1% | +4.9% | -4.0% |
| Net MarginNet income ÷ Revenue | +7.1% | -43117.4% | -43.5% | -0.3% | -194.9% |
| FCF MarginFCF ÷ Revenue | +21.1% | +35.2% | +2.6% | +1.5% | -2.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -23.6% | -11.3% | -7.2% | +2.7% | +7.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -76.3% | — | -56.4% | -79.2% | +75.0% |
SIGA leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — EBS and PRGO each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 9.8x trailing earnings, EBS trades at a 31% valuation discount to SIGA's 14.3x P/E. On an enterprise value basis, EBS's 4.0x EV/EBITDA is more attractive than BRKR's 18.4x.
| Metric | EBSEmergent BioSolut… | SIGASIGA Technologies… | PRGOPerrigo Company p… | BRKRBruker Corporation | ABCLAbCellera Biologi… |
|---|---|---|---|---|---|
| Market CapShares × price | $472M | $339M | $1.6B | $6.7B | $1.4B |
| Enterprise ValueMkt cap + debt − cash | $838M | $185M | $5.1B | $8.4B | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | 9.82x | 14.33x | -1.14x | -291.53x | -9.84x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.57x | 2.78x | 5.56x | 20.68x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 4.02x | 7.60x | 7.42x | 18.41x | — |
| Price / SalesMarket cap ÷ Revenue | 0.64x | 3.58x | 0.38x | 1.94x | 19.29x |
| Price / BookPrice ÷ Book value/share | 0.99x | 1.70x | 0.55x | 2.64x | 1.49x |
| Price / FCFMarket cap ÷ FCF | 3.01x | 6.96x | 11.12x | 153.73x | — |
Evenly matched — EBS and PRGO each lead in 2 of 6 comparable metrics.
Profitability & Efficiency
SIGA leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
EBS delivers a 9.6% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-51 for PRGO. SIGA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), EBS scores 7/9 vs ABCL's 3/9, reflecting strong financial health.
| Metric | EBSEmergent BioSolut… | SIGASIGA Technologies… | PRGOPerrigo Company p… | BRKRBruker Corporation | ABCLAbCellera Biologi… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.6% | -10.7% | -50.7% | -0.5% | -15.1% |
| ROA (TTM)Return on assets | +3.7% | -7.4% | -19.8% | -0.2% | -23.3% |
| ROICReturn on invested capital | +8.5% | +33.7% | +3.7% | +4.4% | -16.8% |
| ROCEReturn on capital employed | +9.1% | +11.3% | +4.3% | +5.0% | -23.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 | 4 | 4 | 3 |
| Debt / EquityFinancial leverage | 1.09x | 0.00x | 1.35x | 0.81x | 0.14x |
| Net DebtTotal debt minus cash | $367M | -$154M | $3.4B | $1.7B | $9M |
| Cash & Equiv.Liquid assets | $205M | $155M | $532M | $299M | $129M |
| Total DebtShort + long-term debt | $572M | $595,169 | $4.0B | $2.0B | $137M |
| Interest CoverageEBIT ÷ Interest expense | 1.84x | — | -7.20x | 1.14x | -9.52x |
SIGA leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
SIGA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SIGA five years ago would be worth $10,136 today (with dividends reinvested), compared to $1,482 for EBS. Over the past 12 months, ABCL leads with a +139.8% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors SIGA at 6.9% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | EBSEmergent BioSolut… | SIGASIGA Technologies… | PRGOPerrigo Company p… | BRKRBruker Corporation | ABCLAbCellera Biologi… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -27.0% | -15.0% | -13.5% | -9.0% | +40.5% |
| 1-Year ReturnPast 12 months | +92.7% | +1.5% | -51.2% | +7.8% | +139.8% |
| 3-Year ReturnCumulative with dividends | +0.2% | +22.2% | -58.1% | -42.5% | -15.6% |
| 5-Year ReturnCumulative with dividends | -85.2% | +1.4% | -60.1% | -35.5% | -83.4% |
| 10-Year ReturnCumulative with dividends | -76.6% | +764.0% | -77.7% | +67.1% | -91.8% |
| CAGR (3Y)Annualised 3-year return | +0.1% | +6.9% | -25.2% | -16.9% | -5.5% |
SIGA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SIGA and BRKR each lead in 1 of 2 comparable metrics.
Risk & Volatility
SIGA is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than ABCL's 2.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BRKR currently trades 77.8% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EBSEmergent BioSolut… | SIGASIGA Technologies… | PRGOPerrigo Company p… | BRKRBruker Corporation | ABCLAbCellera Biologi… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.83x | 1.15x | 1.18x | 1.59x | 2.31x |
| 52-Week HighHighest price in past year | $14.06 | $9.62 | $28.44 | $56.22 | $6.52 |
| 52-Week LowLowest price in past year | $4.72 | $4.29 | $9.23 | $28.53 | $1.94 |
| % of 52W HighCurrent price vs 52-week peak | +65.0% | +49.2% | +41.2% | +77.8% | +73.9% |
| RSI (14)Momentum oscillator 0–100 | 61.4 | 47.0 | 60.9 | 64.8 | 77.5 |
| Avg Volume (50D)Average daily shares traded | 873K | 688K | 3.4M | 1.9M | 4.5M |
Evenly matched — SIGA and BRKR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Evenly matched — SIGA and PRGO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: EBS as "Buy", SIGA as "Buy", PRGO as "Hold", BRKR as "Buy", ABCL as "Buy". Consensus price targets imply 318.5% upside for ABCL (target: $20) vs 19.2% for BRKR (target: $52). For income investors, SIGA offers the higher dividend yield at 12.73% vs BRKR's 0.34%.
| Metric | EBSEmergent BioSolut… | SIGASIGA Technologies… | PRGOPerrigo Company p… | BRKRBruker Corporation | ABCLAbCellera Biologi… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $12.00 | — | $20.00 | $52.13 | $20.17 |
| # AnalystsCovering analysts | 15 | 1 | 36 | 32 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | +12.7% | +9.8% | +0.3% | — |
| Dividend StreakConsecutive years of raises | 1 | 4 | 10 | 0 | — |
| Dividend / ShareAnnual DPS | — | $0.60 | $1.15 | $0.15 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.3% | 0.0% | 0.0% | +0.2% | 0.0% |
Evenly matched — SIGA and PRGO each lead in 1 of 2 comparable metrics.
Key Takeaway
SIGA leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.
Best OverallSIGA Technologies, Inc. (SIGA)Leads 3 of 6 categories
Loading custom metrics...
EBS vs SIGA vs PRGO vs BRKR vs ABCL: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EBS or SIGA or PRGO or BRKR or ABCL a better buy right now?
For growth investors, AbCellera Biologics Inc.
(ABCL) is the stronger pick with 160. 6% revenue growth year-over-year, versus -31. 8% for SIGA Technologies, Inc. (SIGA). Emergent BioSolutions Inc. (EBS) offers the better valuation at 9. 8x trailing P/E (17. 6x forward), making it the more compelling value choice. Analysts rate Emergent BioSolutions Inc. (EBS) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EBS or SIGA or PRGO or BRKR or ABCL?
On trailing P/E, Emergent BioSolutions Inc.
(EBS) is the cheapest at 9. 8x versus SIGA Technologies, Inc. at 14. 3x. On forward P/E, SIGA Technologies, Inc. is actually cheaper at 2. 8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — EBS or SIGA or PRGO or BRKR or ABCL?
Over the past 5 years, SIGA Technologies, Inc.
(SIGA) delivered a total return of +1. 4%, compared to -85. 2% for Emergent BioSolutions Inc. (EBS). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus ABCL's -91. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EBS or SIGA or PRGO or BRKR or ABCL?
By beta (market sensitivity over 5 years), SIGA Technologies, Inc.
(SIGA) is the lower-risk stock at 1. 15β versus AbCellera Biologics Inc. 's 2. 31β — meaning ABCL is approximately 101% more volatile than SIGA relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — EBS or SIGA or PRGO or BRKR or ABCL?
By revenue growth (latest reported year), AbCellera Biologics Inc.
(ABCL) is pulling ahead at 160. 6% versus -31. 8% for SIGA Technologies, Inc. (SIGA). On earnings-per-share growth, the picture is similar: Emergent BioSolutions Inc. grew EPS 125. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, BRKR leads at 10. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EBS or SIGA or PRGO or BRKR or ABCL?
SIGA Technologies, Inc.
(SIGA) is the more profitable company, earning 24. 6% net margin versus -194. 9% for AbCellera Biologics Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SIGA leads at 25. 1% versus -289. 0% for ABCL. At the gross margin level — before operating expenses — SIGA leads at 68. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EBS or SIGA or PRGO or BRKR or ABCL more undervalued right now?
On forward earnings alone, SIGA Technologies, Inc.
(SIGA) trades at 2. 8x forward P/E versus 20. 7x for Bruker Corporation — 17. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABCL: 318. 5% to $20. 17.
08Which pays a better dividend — EBS or SIGA or PRGO or BRKR or ABCL?
In this comparison, SIGA (12.
7% yield), PRGO (9. 8% yield), BRKR (0. 3% yield) pay a dividend. EBS, ABCL do not pay a meaningful dividend and should not be held primarily for income.
09Is EBS or SIGA or PRGO or BRKR or ABCL better for a retirement portfolio?
For long-horizon retirement investors, SIGA Technologies, Inc.
(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). AbCellera Biologics Inc. (ABCL) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, ABCL: -91. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EBS and SIGA and PRGO and BRKR and ABCL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EBS is a small-cap deep-value stock; SIGA is a small-cap deep-value stock; PRGO is a small-cap income-oriented stock; BRKR is a small-cap quality compounder stock; ABCL is a small-cap high-growth stock. SIGA, PRGO pay a dividend while EBS, BRKR, ABCL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(EBS: -23.6% · SIGA: -11.3%)P/E Ratio<
x
(EBS: 9.8x · SIGA: 14.3x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.